Spectral Med Inc - Asset Resilience Ratio
Spectral Med Inc (EDT) has an Asset Resilience Ratio of 11.67% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read EDT current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2023)
This chart shows how Spectral Med Inc's Asset Resilience Ratio has changed over time. See Spectral Med Inc (EDT) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Spectral Med Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Spectral Med Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$608.00K | 11.67% |
| Total Liquid Assets | CA$608.00K | 11.67% |
Asset Resilience Insights
- Moderate Liquidity: Spectral Med Inc has 11.67% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Spectral Med Inc Industry Peers by Asset Resilience Ratio
Compare Spectral Med Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Spectral Med Inc (2005–2023)
The table below shows the annual Asset Resilience Ratio data for Spectral Med Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 11.67% | CA$608.00K ≈ $439.82K |
CA$5.21 Million ≈ $3.77 Million |
+9.66pp |
| 2022-12-31 | 2.01% | CA$241.00K ≈ $174.34K |
CA$12.00 Million ≈ $8.68 Million |
-4.20pp |
| 2021-12-31 | 6.21% | CA$717.00K ≈ $518.67K |
CA$11.55 Million ≈ $8.36 Million |
+3.36pp |
| 2020-12-31 | 2.84% | CA$232.00K ≈ $167.83K |
CA$8.16 Million ≈ $5.90 Million |
+1.24pp |
| 2019-12-31 | 1.60% | CA$64.00K ≈ $46.30K |
CA$4.01 Million ≈ $2.90 Million |
-0.61pp |
| 2018-12-31 | 2.21% | CA$154.00K ≈ $111.40K |
CA$6.98 Million ≈ $5.05 Million |
-40.84pp |
| 2017-12-31 | 43.05% | CA$1.50 Million ≈ $1.08 Million |
CA$3.47 Million ≈ $2.51 Million |
-30.56pp |
| 2016-12-31 | 73.61% | CA$5.23 Million ≈ $3.78 Million |
CA$7.10 Million ≈ $5.14 Million |
+73.12pp |
| 2015-12-31 | 0.48% | CA$41.00K ≈ $29.66K |
CA$8.46 Million ≈ $6.12 Million |
+0.34pp |
| 2014-12-31 | 0.14% | CA$17.00K ≈ $12.30K |
CA$11.86 Million ≈ $8.58 Million |
-0.04pp |
| 2013-12-31 | 0.18% | CA$17.00K ≈ $12.30K |
CA$9.44 Million ≈ $6.83 Million |
-40.64pp |
| 2012-12-31 | 40.82% | CA$5.14 Million ≈ $3.72 Million |
CA$12.59 Million ≈ $9.10 Million |
+16.19pp |
| 2011-12-31 | 24.63% | CA$5.09 Million ≈ $3.68 Million |
CA$20.65 Million ≈ $14.94 Million |
-4.40pp |
| 2010-12-31 | 29.03% | CA$5.02 Million ≈ $3.63 Million |
CA$17.30 Million ≈ $12.51 Million |
-27.43pp |
| 2008-12-31 | 56.46% | CA$4.00 Million ≈ $2.89 Million |
CA$7.08 Million ≈ $5.13 Million |
+2.71pp |
| 2007-12-31 | 53.75% | CA$4.29 Million ≈ $3.10 Million |
CA$7.98 Million ≈ $5.77 Million |
-0.43pp |
| 2006-12-31 | 54.17% | CA$5.06 Million ≈ $3.66 Million |
CA$9.34 Million ≈ $6.75 Million |
+25.19pp |
| 2005-12-31 | 28.98% | CA$3.35 Million ≈ $2.42 Million |
CA$11.56 Million ≈ $8.36 Million |
-- |
About Spectral Med Inc
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device … Read more